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Background: Attention deficit hyperactivity disorder (ADHD) is a prevalent neurode-
velopmental disorder affecting children, adolescents, and adults. Its etiology is not well 
understood, but it is increasingly believed to result from diverse pathophysiologies that 
affect the structure and function of specific brain circuits. Although one of the best-stud-
ied neurobiological abnormalities in ADHD is reduced fronto-striatal-cerebellar gray 
matter (GM) volume, its specific genetic correlates are largely unknown.
Methods: In this study, T1-weighted MR images of brain structure were collected from 
198 adolescents (63 ADHD-diagnosed). A multivariate parallel independent component 
analysis (Para-ICA) technique-identified imaging genetic relationships between regional 
GM volume and single nucleotide polymorphism data.
results: Para-ICA analyses extracted 14 components from genetic data and 9 from 
MR  data. An iterative cross-validation using randomly chosen subsamples indicated 
acceptable stability of these ICA solutions. A series of partial correlation analyses con-
trolling for age, sex, and ethnicity revealed two genotype–phenotype component pairs 
significantly differed between ADHD and non-ADHD groups, after a Bonferroni correction 
for multiple comparisons. The brain phenotype component not only included structures 
frequently found to have abnormally low volume in previous ADHD studies but was also 
significantly associated with ADHD differences in symptom severity and performance on 
cognitive tests frequently found to be impaired in patients diagnosed with the disorder. 
Pathway analysis of the genotype component identified several different biological path-
ways linked to these structural abnormalities in ADHD.
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inTrODUcTiOn
Attention deficit hyperactivity disorder (ADHD) is a complex 
neurodevelopmental disorder (1) whose etiology is not fully 
understood. In attempts to understand its strong (70–80%) herit-
ability (2, 3), linkage studies have identified potential susceptibil-
ity loci on reported chromosomal regions, including 16p13 and 
17p11 (3). Candidate-gene studies have implicated some single 
nucleotide polymorphisms (SNPs) associated with dopaminer-
gic (DA), serotonergic, and noradrenergic systems implicated 
by pharmacologic response and neuroimaging research (3, 4). 
A few genome-wide association studies (GWAS) have found evi-
dence that CDH13, GFOD1, FBXO33, and SLC9A9 genes might 
be associated with ADHD (3, 5). Quantitative trait analysis of 
ADHD has shown associations between inattentive and hyperac-
tive/impulsive symptoms and variations in glutamate receptor 
GRIN2B subunit genes (6). Also, GRIN2A and GRIN2B are 
reported to play role in neurodevelopment (7). While these find-
ings represent a starting place, ADHD is believed to be a polygenic 
disorder that arises from the contributions of numerous known 
and yet-to-be-identified gene variants (8), along with noteworthy 
evidence for social, environmental, and/or gene × environment 
interactions (9, 10).
For such a complex disorder, simply identifying associations 
between genes and the broad diagnostic phenotype might not 
increase understanding as precisely or as rapidly as identifying 
links between the genes and specific features of the disorder, such 
as neuroimaging-measured brain structure (11). Meta-analyses of 
ADHD brain structure studies have revealed that ADHD samples 
often show reduced total and right cerebral gray matter (GM), 
cerebellum, right caudate, right putamen, and globus pallidus 
volumes (12, 13). Also, the parietal cortex and hippocampus are 
often, though less consistently, found to be abnormal in ADHD 
(10). One of the most reliable findings in ADHD is reduced fron-
tal lobe volume or cortical thickness (10, 12–14) particularly in 
the right frontal lobe, which includes brain regions linked to the 
types of cognitive and executive impairments frequently found 
in ADHD (15).
Neuroimaging genetics approaches offer potential under-
standing of biological pathways related to numerous, likely 
interacting genes and specific mechanisms of brain growth and 
function that contribute to inherited behavioral and neuropsy-
chiatric diseases. However, it remains statistically challenging to 
identify such genes. Univariate GWAS methods are constrained 
by large sample size requirements to detect the weak effects char-
acteristic of common disease/common variant models, given the 
need to Bonferroni correction for number of SNPs evaluated. In 
recent years, multivariate analysis techniques, such as parallel 
independent component analysis (Para-ICA), have been devel-
oped. These techniques identify relationships between clusters 
of interrelated SNPs and complex phenotypic characteristics 
(e.g., brain structure) in a data-driven manner (16, 17). Para-
ICA has been used successfully in imaging genetics studies (18) 
to yield robust, theoretically informative results with practical 
sample sizes (19, 20). Such multivariate techniques have a use-
ful role in discovering likely relationships between genes and 
neurobiology within a psychiatric disorder, which then can be 
explored using conventional genetic approaches. Moreover, 
Para-ICA is particularly well suited in identifying and then 
annotating aggregates (or “networks”) of genes that contribute 
to particular physiological pathways. Pathway analysis using 
currently available maps [e.g., Kyoto Encyclopedia of Genes and 
Genomes (KEGG)] (21) of molecular interactions that could 
underlie biological processes or disease might rapidly advance 
our understanding of disorder pathophysiology. For instance, 
ADHD researchers have found that specific physiological path-
ways are linked to the broad ADHD phenotype (22), specific 
ADHD symptoms (23), or cognitive performance patterns 
within ADHD samples (24).
Because GWAS analysis are beyond the capability of the typi-
cal sample sizes collected in neuroimaging studies, we are not 
interested in attempting to link genes to broad ADHD behavioral 
phenotype. However, Para-ICA is ideally suited for identifying 
novel brain structure intermediate phenotypes in sample of 
modest size by linking aggregates of SNPs to specific GM volume 
characteristics already known to be relevant to ADHD. We used 
Para-ICA to elucidate the relationships between regional GM 
measurements previously found to be abnormal in ADHD and 
clusters of SNPs from an arrayof >240,000 putatively functional 
exomic markers. Specifically, we assessed genetic relationships 
of structural GM in DSM-IV-combined subtype ADHD with 
relatively low rates of psychiatric comorbidity and healthy com-
parison adolescents, simultaneously, by identifying what aspects 
of brain structure or genotype covaried systematically across the 
sample to form independent component (IC) aggregates. The 
study used Illumina HumanExome-12v1-2 chip (Illumina, San 
Diego, CA, USA) for genotyping and a voxel-based morphom-
etry (VBM) approach (25) to characterize participants’ voxel-
wise GM volume obtained from T1-weighted MRI scans of brain 
structure. The content of these components is determined from 
natural aggregation found within each datatype. Thus, it is not 
possible to specify a priori the content of different components 
within the genetic or the neuroimaging modalities. Instead, 
components are assigned simple names for convenient labeling 
conclusion: Some of these pathways implicate well-known dopaminergic neurotrans-
mission and neurodevelopment hypothesized to be abnormal in ADHD. Other more 
recently implicated pathways included glutamatergic and GABA-eric physiological 
systems; others might reflect sources of shared liability to disturbances commonly found 
in ADHD, such as sleep abnormalities.
Keywords: genetics, aDhD, sMri, parallel ica, neurodevelopmental disorder
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(e.g., G1, G2, etc. for genetic data or S1, S2, etc. for brain struc-
ture data) so they can be later described in detail after group-
based hypothesis-testing, which determines their relevance to 
the disorder. To identify genetic neuroimaging relationships 
that differed between ADHD and non-ADHD, we extracted 
subject-dependent loading coefficients (LCs) of each IC for 
random effects statistical testing. Finally, for those component 
pairs (e.g., G1–S2) that differed between study groups, we char-
acterized various molecular biological pathways associated with 
detected gene aggregates to provide information about possible 
physiological processes that might have given rise to the ADHD 
brain structure abnormalities detected. We hypothesized that 
brain phenotype component depicting ADHD-relevant regions 
(fronto-striatal, fronto-parietal, or cerebellar) would be associ-
ated with specific gene networks related to brain development 
and catecholaminergic neurotransmission. Furthermore, we 
predicted that ADHD subjects would show differences in both 
brain phenotypes and gene networks when compared to healthy 
controls. To enrich results interpretation, post hoc tests explored 
relationships between Para-ICA-derived LCs and ADHD clinical 
features.
MaTerials anD MeThODs
All study procedures were approved by Hartford Hospital’s 
Institutional Review Board. Written permission was obtained 
from parents/legal guardians of all participants, and assent was 
obtained from all participants under the age of 18. The sample 
comprised 63 community-recruited patients diagnosed with the 
combined subtype of ADHD (DSM-IV 314.01) and 135 healthy 
comparison participants. Psychiatric diagnoses for research 
purposes of all DSM-IV Axis I disorders were made using the 
Kiddie-Schedule for Affective Disorders and Schizophrenia-
Present and Lifetime version (K-SADS-PL) (26) conducted by 
trained clinical research staff, under the supervision of a licensed 
clinical psychologist (Michael C. Stevens). Separate collateral 
interviews with at least one parent/guardian were incorporated 
into diagnostic decisions made after synthesizing information 
in weekly research group meetings. Participants were excluded 
if they (a) had lifetime history of bipolar disorder, psychotic 
disorder, obsessive–compulsive disorder, PTSD, Tourette’s disor-
der, pervasive developmental disorder; (b) had current DSM-IV 
substance dependence, major depressive disorder, or anxiety 
disorder; (c) had IQ estimate <80 determined by Wechsler 
abbreviated Scale of Intelligence; or (d) were taking Wellbutrin 
(Buproprion), Strattera (Atomoxetine HCl), Cylert (Pemoline), 
or Provigil (Modafinil). Sample characteristics are shown in 
Table S1 in Supplementary Material. Clinical assessment was 
supplemented with parent-reported Brown attention deficit 
disorder (ADD) scale (27) scores and performance on Conner’s 
continuous performance test (CPT-II) (28).
structural Mri and Data Preparation
Structural MR images were obtained using a Siemens 3T Allegra 
MRI scanner at Olin Neuropsychiatry Research Center at 
Hartford Hospital (3D MPRAGE; TR = 2300 ms, TE = 2.74 ms, 
TI  =  900  ms, flip angle  =  8°, FOV  =  17  mm  ×  256  mm, 
matrix = 176 × 256 × 176, voxel size = 1 mm × 1 mm × 1 mm, 
pixel bandwidth = 190 Hz; 7.09 min). MR images were examined 
and processed using VBM8 toolbox (29) with default settings, as 
follows: (i) bias-correction, (ii) tissue classification, (iii) spatial 
normalization to Montreal Neurological Institute (MNI) space, 
(iv) high dimensional non-linear diffeomorphic anatomical 
registration through exponentiated lie algebra (DARTEL) nor-
malization, and (v) finally, the normalized GM segments were 
modulated to correct and preserve original local volume change. 
The processing pipeline is explained in detail in the VBM8 tutori-
al.1 Modulated GM volumes were smoothed with 4 mm full width 
half maximum Gaussian kernel.
snPs Data collection and Preprocessing
Genomic DNA was extracted from saliva collected from each 
participant using Oragene collection kits (30). The Illumina 
HumanExome-12v1-2 chip was used for genotyping. Genotype 
data were preprocessed using PLINK software (31) following 
quality control steps (32) detailed in Figure  1. SNPs in high 
linkage disequilibrium (LD) were removed (window size of 
SNPs = 50, number of SNPs to shift the window at each step = 5 
and r2 = 0.7) to increase independence between markers. Custom 
Matlab scripts using an algorithm similar to EIGENSTRAT (33) 
performed principal component analysis of the genetic dataset. 
To correct for population stratification bias, genetic data were 
corrected using top two eigenvectors that showed significance 
association with self-reported race/ethnicity. Logistic regression 
(adjusting for age, sex, and top two eigenvectors representing self-
reported ethnicity) was performed to clean the data and reduce 
the number of SNPs. SNPs showing association with ADHD 
(uncorrected p-value < 0.1) were considered for further analysis. 
The total number of SNPs further considered with Para-ICA was 
3139 (see Table S2 in Supplementary Material for complete list of 
SNPs and their associated genes used for Para-ICA). The entire 
set of markers was annotated to genes based on their coordinates 
using ANNOVAR software (34).
Parallel independent component analysis
Parallel independent component analysis between SNPs data and 
modulated GM volume used the Fusion ICA Toolbox2 within 
Matlab 7.7. Practical implementation of Para-ICA for gene 
and MRI data is explained in detail in a recent review paper 
(18), and an overview is shown in Figure S1 in Supplementary 
Material. Because our study goals using Para-ICA technique 
have numerous, important differences from a GWAS analysis 
approach that has been highly influential in psychiatric genetics, 
it is useful to briefly review the methods involved to highlight 
the different expectations involved. Para-ICA is a data-driven 
approach that estimates maximally ICs within gene and brain 
phenotype data separately and also maximizes the association 
between modalities using an entropy term based on information 
theory (16–18). The goal of Para-ICA is not to identify single 
gene association. Instead, ICA is run separately, in parallel, on 
1 http://dbm.neuro.uni-jena.de/vbm8/VBM8-Manual.pdf
2 http://mialab.mrn.org/software/fit/
FigUre 1 | illustration of quality control processing for snP data and structural Mr imaging data.
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both modalities to identify collections of interrelated SNPs and 
to isolate specific features within the brain structure maps that 
systematically covary across participants. Not only do the com-
ponents identified by Para-ICA represent meaningful aggregates 
but also the number of subsequent statistical tests gets reduced 
substantially. Thus, Para-ICA allows us to confidently assess the 
relationship between modalities (e.g., genetic and MRI data) as 
well as group difference (e.g., patient versus controls) for each 
component of each modality in moderate-sized samples. As such, 
it is ideal to identify relationships between modalities within a 
specific disorder that otherwise would require tens of thousands 
of participants using GWAS techniques. Although techniques 
like Para-ICA can help to rapidly advance our understanding 
of complex gene–brain disorder relationships, in many applica-
tions, it should be considered exploratory, with its results needing 
replication.
For the current analysis, the ratio of sample size to number 
of SNPs (198/3139) in our study is consistent with validation 
work showing that Para-ICA will provide accurate results (35). 
The number of ICs estimated using minimum description 
length criteria (18, 36) was 14 for genetic data and 9 for MRI 
data. Importantly, because full replication was not possible 
given the data available, the consistency and stability of the 
components was examined using leave-N-subjects-out (5% of 
total subjects) cross-validation technique (18, 37), run iteratively 
across randomly chosen sub-samples. This reliability validation 
method revealed that the stability of genetic and brain phenotype 
components were acceptable – 70 and 90%, respectively. The LCs 
for each component ×  modality ×  subject were extracted, and 
partial correlation [controlling for age, sex, top two eigenvec-
tors representing self-reported ethnicity, and group association 
vector (ADHD versus HC)] between LCs of both modalities was 
computed in SPSS v19.0 (IBM, Inc.). Component pairs that sur-
vived Bonferroni correction for multiple comparison [p < 0.05/
(9 × 14)] were examined for post hoc pairwise group differences. 
To correct for gene size bias and select dominant genes in a 
component, gene-based association values were calculated using 
VEGAS software (38). To define dominant regions of component 
maps, an arbitrary threshold of |z| > 1.5 and cluster size k > 50 
voxels was selected. To enrich possible interpretation of the 
ICs identified by Para-ICA, we also assessed linear associations 
between clinical measures (e.g., symptom sums or cognitive test 
scores) and Para-ICA-derived genetic and phenotype compo-
nents, controlling for age and sex. Because these were exploratory 
post hoc analyses, significant correlations (p < 0.05, uncorrected) 
are reported.
TaBle 1 | significant brain phenotype–genetic component association.
Brain phenotype 
component
genetic  
component
r p-value
S1 G1 0.34 1 × 10−6
S1 G2 −0.34 9 × 10−7
S2 G1 −0.41 2 × 10−9
S2 G2 0.31 1 × 10−5
S3 G3 −0.32 4 × 10−6
S1–S3, brain phenotype independent components; G1–G3, genetic independent 
components; r, Pearson’s correlation.
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genetic Pathway analysis
To identify underlying biological pathways of the gene sets, we 
used the ConsensusPath database.3 Only genes that showed 
gene-based trait association of p-value < 0.05 were selected for 
pathway enrichment analysis. The lists of significant genes of 
component G2 (after gene size correction) are listed in Table S3 
in Supplementary Material. The p-value for each pathway is 
calculated using a hypergeometric approach based on number of 
genes in both user-specified gene set and genes associated with 
each pathway. The significance values were FDR-adjusted to cor-
rect for multiple comparison (39).
resUlTs
genotype–Phenotype associations
Partial correlation analysis of component coefficients revealed sig-
nificant associations among five phenotype–genotype component 
pairs. Three brain phenotype ICs (designated as S1, S2, and S3) 
showed significant correlation with three genetic ICs (designated 
as G1, G2, and G3). Pearson’s correlation coefficients (along with 
their associated p-value) of genetic ICs and brain phenotype ICs 
are listed in Table 1. Of these, the S1–G2 and S2–G2 pairs showed 
a study group difference in LCs for both the genetic and brain 
phenotype components (Figure 2), making these components of 
primary interest to our study aims. Levene’s test for equality of 
variances confirmed the variance between groups were similar.
Figures 3 and 4 depict these S1–G2 and S2–G2 component 
pairs. For both, ADHD participants showed a stronger genotype–
phenotype relationship than non-ADHD. The significant brain 
regions in brain phenotype components S1 and S2 are listed in 
Tables S4 and S5 in Supplementary Material respectively, and are 
shown in Figures 3B and 4B respectively. The most prominent 
regions within brain phenotype component S1 were anterior/
mid-cingulate gyrus and bilateral anterior insula. Bilateral basal 
ganglia (caudate and both dorsal and ventral putamen), mid-cin-
gulate, and thalamus were the most strongly implicated regions in 
S2. Both components included other brain regions, although with 
lower evidence for their association with the component. S1 also 
contained bilateral cerebellum, posterior cingulate, thalamus, 
fusiform, and parahippocampus gyrus. S2 also included cerebel-
lum, mid- and posterior cingulate, fusiform, rostral cingulate/
3 http://cpdb.molgen.mpg.de/
orbitofrontal cortex, and thalamus. Many of these other regions 
also have been found to be structurally abnormal in ADHD. 
Overlap between the brain phenotype components was seen only 
in regions of anterior and posterior cingulate, differing in how 
strongly they loaded on each component (e.g., anterior cingulate 
loading strongest for S1; posterior cingulate for S2).
Post hoc testing revealed correlations between S2’s LCs 
and scores on the Brown ADD scale’s attention [r  =  0.32, 
p(uncorrected) = 0.03], effort [r = 0.37, p(uncorrected) = 0.01], 
affect [r =  0.34, p(uncorrected) =  0.02], and working memory 
[r = 0.38, p(uncorrected) = 0.01] scores. The Brown ADD scale 
effort score also showed correlation between S1’s LCs [r = −0.30, 
p(uncorrected) =  0.04]. Also, the S2 LCs were correlated with 
the CPT-II omission [r  =  0.45, p(uncorrected)  =  0.002] and 
variability [r = 0.32, p(uncorrected) = 0.03] standardized scores. 
The LCs of the G1 correlated with CPT-II Omission [r = 0.33, 
p(uncorrected) = 0.02]. Although none of the correlations sur-
vived multiple comparison correction when tested as a complete 
set, these exploratory results reinforce the relevance of these brain 
phenotype components to clinically relevant ADHD dysfunction. 
ADHD symptom severity (i.e., K-SADS-PL symptom count) was 
uncorrelated with either genotype or phenotype LCs.
The S3–G3 pair was less informative for our primary objec-
tive. Although knowing what SNPs are associated with this 
collection of brain regions is valuable, neither its phenotype 
nor genotype component coefficients differed between groups. 
Brain regions comprising the S3 component are listed in 
Table  S6 in Supplementary Material and depicted in Figure S2 
in Supplementary Material. Figure S2 in Supplementary Material 
also depicts scatterplots of the other significantly linked brain 
phenotype and genotype component pairs that are not further 
considered.
Pathway enrichment analysis
Significant KEGG pathways associated with G2-identified genop-
types along with uncorrected p and corrected q values are listed in 
Table 2. These included pathways involved in neurotransmission 
(glutamatergic synapse, DA synapse, retrogade endocannabi-
noid signaling, GABAergic synapse, and cholinergic synapse), 
neurodevelopment (Rap1 signaling, neuroactive ligand–receptor 
interaction), and other functions, such as circadian entrainment, 
insulin secretion, hypertropic cardiomyopathy, dilated car-
diomyopathy, the estrogen signaling pathway, and endocytosis. 
As discussed below, these pathways represent a diverse mix of 
biological systems – some are already known to be implicated in 
ADHD, while others represent relatively novel findings for the 
disorder.
DiscUssiOn
By using multivariate Para-ICA to link specific GM volume 
measurements often found to be abnormal in ADHD with sev-
eral genetic pathways, we showed that specific ADHD-relevant 
GM volume deficits can be linked to constellations of genes 
implicated in different physiological pathways. The importance 
FigUre 2 | Bar plot of mean loading coefficients of brain phenotype component and genetic component. * indicates group differences among ADHD and 
HC with p < 0.05. HC, healthy controls; ADHD, attention deficit hyperactive disorder.
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of this should not be overlooked, as most prior studies have been 
able to link single or very small numbers of specific genotypes to 
the broad ADHD diagnostic phenotype, not comparatively large 
genotype, aggregates to specific neurobiological features known 
to be abnormal in the disorder.
We discuss two of the three phenotype components (S1 
and S2; see Figures  3B and 4B) that showed ADHD versus 
non-ADHD differences (Figure  2) and whose correlation with 
cognitive performance or parent-reported clinical impairments 
showed that genetic factors explain a noteworthy portion of 
specific GM volume phenotypic variability relevant to ADHD. 
The most prominent brain regions in S1 and S2 phenotype 
components were cingulate and basal ganglia, respectively. These 
were the only regions to emerge as consistently abnormal in the 
most recent ADHD VBM meta-analysis (40). Along with insular 
cortex (the other most prominent regions within S1), the anterior 
cingulate forms a functionally integrated neural circuit (41, 42) 
reliably linked to attention, conflict resolution, performance 
monitoring, and switching among cognitive states (14, 43, 44) 
and whose reduced GM volume has been linked to abnormal 
attention modulation and inhibitory capacity in ADHD (15). 
Putamen relevance to ADHD is shown by frequent reports of 
volume abnormality (13, 45), ADHD-like behavior following 
lesions (46), and correlation between ADHD symptoms and 
functional abnormalities (47). S1 and S2 also contained parietal 
and cerebellar regions, which also are implicated in ADHD (13, 
14, 40, 43, 45, 48). Taken collectively, Para-ICA identified the 
specific ADHD GM volume abnormalities in ADHD that would 
be predicted by proposals for multi-systemic neural impairment 
in ADHD in fronto-striatal (49, 50) and fronto-cerebellar (11, 49) 
neural circuits (51).
We show for the first time that these specific brain phenotypes 
had genetic correlates  –  the aggregate of genes in the G2 IC. 
Although the single genes we found should be noted for future 
ADHD genetic experiments, interpretation of single genes would 
be premature pending GWAS replication. However, pathway 
analysis suggests several possible biological/molecular influences 
on brain volume that could potentially mediate disease risk in 
ADHD – some familiar, others more novel. We hypothesized that 
neurodevelopmental biological pathways logically would predict 
some aspects of ADHD brain structure abnormality. We found 
the brain phenotype components were related to differences in 
FigUre 3 | (a) Scatter plots of loading coefficient of brain phenotype component S1 and genetic component G2. Scatter plot and line in red and cyan color 
indicates ADHD and HC group, respectively. (B) Significant regions in S1. Brain slices shown in the above figure are x = −6, y = 46, and z = −3 in Montreal 
Neurological Institute (MNI) space.
FigUre 4 | (a) Scatter plots of loading coefficient of brain phenotype component S2 and genetic component G2. Scatter plot and line in red and cyan color 
indicates ADHD and HC group, respectively. (B) Significant regions in S2. Brain slices shown in the above figure are x = −4, y = 13, and z = −6 in Montreal 
Neurological Institute (MNI) space.
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TaBle 2 | significant Kegg pathways for g2.
Pathway Overlapping genes p-value q-value
Cholinergic synapse CREB3L2; GNG4; 
CACNA1C; ADCY9; CHRNA7
0.002 0.015
Hypertrophic 
cardiomyopathy 
(HCM)
CACNA1C; ITGB6; ACE; 
CACNB4
0.004 0.015
GABAergic synapse GABRB1; GNG4; CACNA1C; 
ADCY9
0.005 0.015
Insulin secretion CREB3L2; CACNA1C; 
ADCY9; ADCYAP1
0.005 0.015
Dilated 
cardiomyopathy
CACNA1C; ITGB6; ADCY9; 
CACNB4
0.006 0.015
Circadian 
entrainment
GRIN2B; GNG4; CACNA1C; 
ADCY9
0.007 0.015
Rap1 signaling 
pathway
TEK; PDGFD; ADCY9; 
DOCK4; GRIN2B; SIPA1L1
0.007 0.015
Adrenergic signaling 
in cardiomyocytes
CREB3L2; ADRB2; 
CACNA1C; ADCY9; CACNB4
0.008 0.015
Retrograde 
endocannabinoid 
signaling
GABRB1; GNG4; CACNA1C; 
ADCY9
0.008 0.015
Endocytosis VPS37C; NTRK1; AGAP1; 
ADRB2; TFRC; HSPA1L
0.008 0.015
Glutamatergic 
synapse
GRIN2B; GNG4; CACNA1C; 
ADCY9
0.011 0.020
Neuroactive ligand–
receptor interaction
NTSR2; GRIN2B; ADRB2; 
CHRNA7; GABRB1; HCRTR2
0.014 0.023
Dopaminergic 
synapse
CREB3L2; GRIN2B; GNG4; 
CACNA1C
0.019 0.027
cAMP signaling 
pathway
CREB3L2; GRIN2B; ADRB2; 
CACNA1C; ADCY9
0.020 0.027
Ras signaling 
pathway
GRIN2B; GNG4; TEK; 
PDGFD; RASGRF2
0.034 0.043
KEGG, Kyoto Encyclopedia of Genes and Genomes; GABA, gamma-aminobutyric 
acid; Rap1, Ras-related protein 1; cAMP, Cyclic adenosine monophosphate.
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expression of a neuroactive ligand–receptor interaction pathway, 
which has been linked to neurodevelopment and is associated 
with various psychiatric disorders (52, 53), and also to a specific 
signal transduction pathway, i.e., Rap1 (ras-related protein 1), 
whose pathway involves cell adhesion and regulation of mitogen-
activated protein kinase that are important for neural develop-
ment (54, 55) in the form of neocortical neuronal migration and 
lamination (56). Rap1 is a key mediator of calcium regulation of 
CREB-dependent transcription and dendritic development that 
are responsible for neural development (57, 58). Rap1 signaling 
pathways are plausibly implicated in cortical and subcortical 
neurodevelopment that may be relevant to ADHD. Future stud-
ies might test if these pathways are related to brain development 
delays, where frontal, temporal, and basal ganglia brain regions 
lag behind non-ADHD peers by an average of 3 years (59).
Another study prediction was that we would identify specific 
DA- and norepinephrine (NE)-related genotypes that would be 
associated with the ADHD brain structure abnormalities. The 
genes in the G1 component implicate a pathway involved with 
DA-related synaptic structure and function (see Table 2), some 
of which directly involve DA neurotransmission DRD2 (D2 
receptor) (60) and DDC  –  a general non-specific precursor of 
DA and 5HT synthesis (61). There are long-standing theories of 
dysfunctional catecholaminergic function in ADHD mesocorti-
cal and mesolimbic DA systems (62, 63). ADHD findings include 
abnormally increased DA receptor density in those specific 
fronto-striatal regions that can be adequately assessed using avail-
able positron emission tomography ligands (64), and evidence 
that psychostimulant medications work in large part because of 
their ability to increase synaptic DA levels by blocking the DA 
transporter (65). Although the precise mechanisms underlying 
DA dysfunction in ADHD are incompletely understood, much 
recent inquiry has involved the ways in which DA and its NE exert 
neuromodulatory effects on widespread brain regions important 
in ADHD and other developmental psychiatric disorders (66, 67).
Many of the same genes identified by Para-ICA related to DA 
synapses also have been linked to KEGG pathways for glutamate, 
GABA, and cholinergic synapses, as well as retrograde endocan-
nabinoid signaling. Previous research has implicated all these 
neurotransmitter systems in ADHD (68), and the current results 
should serve to bolster interest in exploring the role of these other 
systems in the pathophysiology of ADHD. In particular, the glu-
tamatergic system is implicated by several lines of evidence (69). 
Not only has previous genome-wide analysis identified possible 
association with genes involved in synaptic adhesion, glutamate 
receptors, and intracellular signaling pathways in ADHD but 
also there are magnetic resonance spectroscopy (MRS)-detected 
fronto-striatal glutamate metabolite abnormalities in ADHD (70, 
71). Several mouse models (72, 73) highlight the interactive impact 
of glutamatergic genotypes on dopamine-related brain function 
and ADHD behaviors like hyperactivity (74). Glutamate/GABA 
interactions have long been the focus of inquiry with respect to 
regional cellular excitation/inhibition balance, and recent fMRI 
study also has linked them to task-induced activity, intrinsic 
activity within the brain’s “default mode,” and functional integra-
tion of widely distributed neural networks (75). Such interactions 
at the synaptic level could be related to ADHD pathophysiology. 
Less prevalent in ADHD prior research is the endocannabinoid 
system. CB1 and CB2 receptors are expressed most strongly in 
the basal ganglia that formed parts of the S2 brain phenotype 
component (76). This system is involved in medial prefrontal 
cortical (mPFC) dopamine release through changes in GABA 
inhibitory synapse (77), and there are numerous instances of 
interaction between these two neurotransmitter systems (78, 
79), including those in rodents ADHD models (80). Finally, the 
retrograde endocannabinoid signaling pathway has been impli-
cated in impulsivity (20). The GABAergic system contributes to 
impulsivity-related brain function and behavior (81), e.g., rodent 
studies suggest that impaired synaptic integration of DA and glu-
tamatergic afferents targeting GABAergic medium-spiny neurons 
are associated with impulsivity (82). A recent MRS study revealed 
reduced GABA concentration in ADHD patients (83). A previous 
rodent study also has implicated GABA in ADHD by showing 
that the loss of GABAergic interneurons in cortex was associated 
with motor hyperactivity (84). In addition, the perturbation of 
synaptic connectivity of GABAergic interneurons was found to 
produce abnormal behaviors relevant to various neuropsychiatric 
disorders (85). Support for a role of acetylcholine systems is found 
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in studies that found choline-containing compounds are altered 
across various brain regions in ADHD patients (68). Moreover, 
acetylcholine and dopamine interactions within the striatum 
modulate dopamine-related neuronal activity that signals moti-
vational salience (86). Finally, Tourette syndrome  –  which is a 
common comorbid condition with ADHD (87) – has been linked 
to reduced basal ganglia volume (88) and deficits of cholinergic 
interneuron in dorsolateral striatum (89).
The implications of the pathways related to circadian entrain-
ment and cAMP signaling are less obviously interpreted. A 
substantial literature has examined the relationship between sleep 
disturbance and ADHD, e.g., delayed circadian rhythmicity in 
ADHD (90, 91), links between impulsivity and circadian entrain-
ment (20), or the role of DA signaling (92). However, specific 
mechanisms have not been identified that have etiological 
relevance to ADHD. This pathway might be added to proposed 
research agenda aimed at understanding the overlap between 
sleep-related brain physiology and known ADHD deficits [e.g., 
neurotransmitters involved in both sleep and attention regula-
tion, or phenotypic similarities between the deleterious effects of 
sleep deprivation and ADHD (93)]. cAMP impairment has been 
suggested by a rat model of ADHD (94) and findings of cAMP 
accumulation and reduced cAMP sensitivity during adolescence 
that might be a mechanism underlying ADHD symptom expres-
sion changes throughout adolescence (95). Additionally, a study 
has reported cAMP-related protein kinase to be responsible for 
dopamine transporter cell-surface redistribution that is involved 
in ADHD (96). A cogent neurobiological model of cAMP involve-
ment in ADHD is needed to guide future research.
The multivariate nature of the Para-ICA results is not eas-
ily reducible to univariate interpretations about specific gene 
function, or about single gene contributions directly to ADHD. 
In other words, individual gene mapped to specific pathways 
does not prove that each gene has a direct casual role in ADHD 
risk. Therefore, we focused our discussion on pathways instead 
of individual genes. In a similar vein, the results should not be 
viewed as definitive until replication, despite the rigor of prior 
Para-ICA method validation and the statistical methods we 
used to assess reliability/consistency. Instead, they are intended 
to accelerate thinking about both familiar and novel pathways 
and their etiological role in ADHD. Overall, our pathway 
results have some similarities with those from previous pathway 
enrichment analyses in ADHD that were conducted to identify 
possible biological mechanisms when GWAS-level statistical 
evidence was not obtained. Both our studies and others have 
found evidence for both synaptic function and plasticity (23, 24, 
97), particularly in the glutamate system, or processes involved 
in neural development (5, 22, 98, 99). Both we and Alemany 
et al. (24) found evidence specifically for the KEGG neuroactive 
ligand–receptor interaction pathway, raising the possibility that 
this pathway might be related to both cognitive performance 
based associations found in that study might be related to the 
brain structure correlates found in this one (i.e., our brain phe-
notype S2 component was linked to CPT-II performance indices 
in post hoc analyses). However, our results join other pathways 
implicated in ADHD – included directed neurite growth (23, 98), 
rRNA processing, CNS development (99), nucleocytoplasmic 
transport, mitochrondrial function (100), protein ubiquitination 
(5), apoptosis, oxidation reduction, and immune response (101). 
A reason we did not find these others might simply be because 
our results are specific to the structural GM volume abnormalities 
found in ADHD – an association that might be closer to etiologi-
cal factors than behavior or clinical impairment. The unexpected 
findings of pathways related to transmission and signaling in 
heart muscle [dilated and hypertrophic cardiomyopathy (HCM) 
and adrenergic signaling in cardiomyocytes], insulin secretion, 
estrogen signaling, and endocytosis likely occurred because many 
of the genes in those systems overlapped with those discussed 
above, including CACNA1C, CACNB4, ITGB6, ACE, ADCY9, 
ADRB2, AGAP1, ARRB1, CREB3L2, FKBP5, HSPA1L, TFRC, and 
VPS37C. Numerous studies have shown these genes are expressed 
in brain, responsible for neurogenesis (102–105), or associated 
with neuropsychiatric disorders (106–109).
limitations
Study limitations include factors like early infant history, nutri-
tion, medication exposure (40, 59), or similar ADHD-relevant 
experiences that might affect neurodevelopment, synaptic prun-
ing, etc., were not measured or controlled as is often done in 
genetic inquiry. Such factors will become more important in any 
replication study, or in studies that examine specific pathophysi-
ological mechanisms suggested by this study. Also our pathway 
analysis was limited by the extent of current knowledge on gene 
products and function (110), which will no doubt improve 
rapidly. Further, using an exome array, we were able to include 
genome-wide exomic information; however, this was not a 
genome-tagging array and could not examine non-exomic vari-
ation directly at all. Finally, as mentioned consistently above, our 
study goal was not to identify single gene associations with the 
ADHD behavioral phenotype, as in GWAS. Instead, our goal was 
to look within a collection of ADHD-relevant genes to determine 
if any relationships could be found with specific aspects of GM 
volume already known to be abnormal in ADHD. While we hope 
the gene–brain structure relationships we found will prompt 
future study of both the gene pathways and the individual genes 
in ADHD, this study is not intended to be a comprehensive 
inquiry of all possible ADHD-related genes. Rather, the point is 
to accelerate identification of novel intermediate endophenotypes 
to be explored in future research. The SNPs identified in current 
study should be further studied to determine whether any of the 
specific genes show a conventional genetic association with either 
the ADHD diagnostic phenotype, specific to the potential brain 
structure intermediate phenotype we described, or if the gene–
brain relationships hold only the implicated biological pathways.
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